Alexander D. Smith
Keine laufenden Positionen mehr
Profil
Alexander D.
Smith held several positions in pharmaceutical development, including Director of Pharmaceutical Development at Triangle Pharmaceuticals, Vice President of Technical Development at Serenex, and Head of Pharmaceutical Development at Fennec Pharmaceuticals.
He also served as Vice President of Product Development at Viamet Pharmaceuticals and Vice President of Drug Product Development at Fulcrum Pharma Developments.
Prior to these roles, he worked as a Principal at UCB Pharma and Burroughs Wellcome.
Smith's most recent position was as Vice President of Technical Operations at G1 Therapeutics from 2015 to 2019.
Smith received his graduate degree from Lehigh University and his undergraduate degree from The University of North Carolina at Charlotte.
Ehemalige bekannte Positionen von Alexander D. Smith
| Unternehmen | Position | Ende |
|---|---|---|
| G1 THERAPEUTICS, INC. | Corporate Officer/Principal | 01.04.2019 |
UCB Pharma, Inc.
 UCB Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services UCB Pharma, Inc. provides research, development & commercialisation of pharmeceutical and biotechnology products. Its products are Keppra, Xyzal, Atarax, Lortab, Dipentum, and Tussionex. UCB Pharma develops small and large molecule treatments for a variety of diseases and ailemts. The company was founded by Emmanuel Janssen in 1928 and is headquartered in Smyrna, GA. | Corporate Officer/Principal | - |
| FENNEC PHARMACEUTICALS INC. | Corporate Officer/Principal | - |
| Burroughs Wellcome | Corporate Officer/Principal | - |
Viamet Pharmaceuticals, Inc.
 Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | Corporate Officer/Principal | - |
Ausbildung von Alexander D. Smith
| The University of North Carolina at Charlotte | Undergraduate Degree |
| Lehigh University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| FENNEC PHARMACEUTICALS INC. | Health Technology |
| G1 THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
Serenex, Inc.
 Serenex, Inc. Pharmaceuticals: MajorHealth Technology Serenex, Inc. operates as a biotechnology company that develops drugs for tumors and cancers of the blood and bone marrow. Its products include drugs for chemotherapy treatments as well as inhibitor compounds. Serenex was founded by George Young and Timothy Haystead in 2000 and is headquartered in Durham, NC. | Health Technology |
Fulcrum Pharma Developments, Inc.
 Fulcrum Pharma Developments, Inc. Pharmaceuticals: MajorHealth Technology Fulcrum Pharma Developments, Inc. was engaged in the discovery and development of drugs. It offered drug development services, strategic analysis, and strategy and planning services. The company was founded in 2002 and was headquartered in Morrisville, NC. | Health Technology |
Triangle Pharmaceuticals, Inc.
 Triangle Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Triangle Pharmaceuticals Inc. provided antiviral drug candidates for the human immunodeficiency virus. The company was founded in 1995 and was located in Durham, NC. | Commercial Services |
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | Health Technology |
| Burroughs Wellcome | |
UCB Pharma, Inc.
UCB Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services UCB Pharma, Inc. provides research, development & commercialisation of pharmeceutical and biotechnology products. Its products are Keppra, Xyzal, Atarax, Lortab, Dipentum, and Tussionex. UCB Pharma develops small and large molecule treatments for a variety of diseases and ailemts. The company was founded by Emmanuel Janssen in 1928 and is headquartered in Smyrna, GA. | Commercial Services |
